BNP Paribas Financial Markets’s Clearside Biomedical CLSD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Hold |
0
| – | -$2 | – | 5583 |
|
|
2025
Q2 | – | Hold |
0
| – | – | – | 5425 |
|
|
2025
Q1 | – | Hold |
0
| – | – | – | 5363 |
|
|
2024
Q4 | – | Hold |
0
| – | – | – | 5386 |
|
|
2024
Q3 | – | Hold |
0
| – | – | – | 4133 |
|
|
2024
Q2 | – | Hold |
0
| – | – | – | 4030 |
|
|
2024
Q1 | – | Hold |
0
| – | – | – | 4019 |
|
|
2023
Q4 | – | Sell |
-14
| Closed | -$200 | – | 3997 |
|
|
2023
Q3 | $184 | Hold |
14
| – | – | ﹤0.01% | 3826 |
|
|
2023
Q2 | $237 | Buy |
+14
| New | +$241 | ﹤0.01% | 3823 |
|
|
2023
Q1 | – | Sell |
-64
| Closed | -$1.24K | – | 3837 |
|
|
2022
Q4 | $1.07K | Sell |
64
-41
| -39% | -$738 | ﹤0.01% | 3797 |
|
|
2022
Q3 | $1.78K | Sell |
105
-809
| -89% | -$17.7K | ﹤0.01% | 4359 |
|
|
2022
Q2 | $20.2K | Sell |
914
-61
| -6% | -$1.48K | ﹤0.01% | 3693 |
|
|
2022
Q1 | $33.5K | Hold |
975
| – | – | ﹤0.01% | 3634 |
|
|
2021
Q4 | $40.2K | Buy |
+975
| New | +$63.1K | ﹤0.01% | 3773 |
|
|
2021
Q3 | – | Hold |
0
| – | – | – | 4002 |
|
|
2021
Q2 | – | Hold |
0
| – | – | – | 4041 |
|
|
2021
Q1 | – | Sell |
-1
| Closed | -$50 | – | 3986 |
|
|
2020
Q4 | $22 | Hold |
1
| – | – | ﹤0.01% | 4099 |
|
|
2020
Q3 | $12 | Hold |
1
| – | – | ﹤0.01% | 4173 |
|
|
2020
Q2 | $15 | Sell |
1
-3
| -75% | -$88 | ﹤0.01% | 4262 |
|
|
2020
Q1 | $99 | Hold |
4
| – | – | ﹤0.01% | 4219 |
|
|
2019
Q4 | $168 | Sell |
4
-206
| -98% | -$4.33K | ﹤0.01% | 4315 |
|
|
2019
Q3 | $1.98K | Hold |
210
| – | – | ﹤0.01% | 4364 |
|
|
2019
Q2 | $3.06K | Sell |
210
-196
| -48% | -$3.5K | ﹤0.01% | 4287 |
|
|
2019
Q1 | $8.4K | Buy |
406
+373
| +1,130% | +$7.4K | ﹤0.01% | 4040 |
|
|
2018
Q4 | $526 | Sell |
33
-28
| -46% | -$1.31K | ﹤0.01% | 4000 |
|
|
2018
Q3 | $5.62K | Hold |
61
| – | – | ﹤0.01% | 4000 |
|
|
2018
Q2 | $9.77K | Sell |
61
-235
| -79% | -$39.6K | ﹤0.01% | 3789 |
|
|
2018
Q1 | $47.6K | Buy |
296
+14
| +5% | +$1.71K | ﹤0.01% | 3589 |
|
|
2017
Q4 | $29.6K | Buy |
282
+149
| +112% | +$16K | ﹤0.01% | 3885 |
|
|
2017
Q3 | $17.4K | Sell |
133
-8
| -6% | -$977 | ﹤0.01% | 3659 |
|
|
2017
Q2 | $19.3K | Buy |
141
+136
| +2,720% | +$16.3K | ﹤0.01% | 3685 |
|
|
2017
Q1 | $588 | Sell |
5
-2
| -29% | -$236 | ﹤0.01% | 3822 |
|
|
2016
Q4 | $957 | Sell |
7
-13
| -65% | -$3.26K | ﹤0.01% | 4019 |
|
|
2016
Q3 | $5.12K | Buy |
+20
| New | +$2.45K | ﹤0.01% | 3381 |
|
Other funds holding CLSD
CG
AWM
GCP
BNP Paribas Financial Markets's CLSD Position: Q3 2025 in Review
BNP Paribas Financial Markets held its Clearside Biomedical (CLSD) position steady in Q3 2025 at 0 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #5583.
BNP Paribas Financial Markets first reported a position in CLSD in Q3 2016 and has held it in 25 quarters since. The position peaked at $47.6K in Q1 2018. 26 funds tracked by Wall St. Rank hold CLSD as of Q3 2025.
- BNP Paribas Financial Markets held 0 shares of Clearside Biomedical worth $0 as of Q3 2025.
- BNP Paribas Financial Markets left its Clearside Biomedical share count unchanged in Q3 2025.
- Clearside Biomedical made up ﹤0.01% of BNP Paribas Financial Markets's portfolio in Q3 2025, its #5583 holding.
- BNP Paribas Financial Markets first reported a position in Clearside Biomedical in Q3 2016 and has held it in 25 quarters since.
- BNP Paribas Financial Markets's Clearside Biomedical position peaked at $47.6K in Q1 2018.
- 26 funds tracked by Wall St. Rank held Clearside Biomedical as of Q3 2025.
Based on BNP Paribas Financial Markets's 13F filing for Q3 2025, filed 13 Nov 2025.